Want to see JP:4594 full AI Analyst Report?
4594 Stock Chart & Stats
¥48.00
¥1.00(2.27%)
At close: 4:00 PM EST
¥48.00
¥1.00(2.27%)
Day’s Range― - ―
52-Week Range¥43.00 - ¥114.00
Previous CloseN/A
Volume188.00K
Average Volume (3M)2.78M
Market Cap
¥6.67B
Enterprise Value¥2.35B
Total Cash (Recent Filing)¥1.30B
Total Debt (Recent Filing)¥500.00M
Price to Earnings (P/E)―
Beta1.01
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-19.27
Shares Outstanding138,891,300
10 Day Avg. Volume4,086,650
30 Day Avg. Volume2,782,203
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)3.25
Price to Sales (P/S)91636.06
P/FCF Ratio-5.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance Sheet BufferVery low leverage reduces refinancing risk and gives management flexibility to fund R&D or absorb operating losses. Sizable assets and equity for its scale provide a multi-month buffer versus creditors, improving survival odds during extended development cycles.
Positive Gross Margins In Recent YearsSustained positive gross margins indicate the company achieves favorable product-level economics when revenue occurs. That structural margin can support future profitability if fixed operating costs are controlled and revenue re‑accelerates from commercial or milestone sources.
Narrowing Losses Vs Earlier YearsA multi-year trend of narrowing losses suggests improving cost discipline or execution on development milestones. If sustained, that trend reduces future fundraising needs and improves prospects for reaching break‑even as products commercialize.
Bears Say
Sustained Negative Cash FlowPersistent annual operating and free cash outflows of over ¥1B create ongoing runway pressure. Without consistent positive cash generation or secured financing, the company faces recurring dilution or distressed funding choices that impair long‑term independence.
Severe Revenue Volatility And CollapseA ~93% revenue drop after a one‑time spike indicates weak commercial traction or dependency on irregular milestone receipts. This structural volatility undermines planning, makes cash forecasts unreliable, and raises execution risk for converting R&D into steady sales.
Recurring Large Operating And Net LossesSustained multi‑hundred-million yen annual losses produce negative returns on equity and force repeated funding rounds or dilution. Ongoing unprofitability limits reinvestment capacity and heightens dependency on external capital across the development timeline.
BrightPath Biotherapeutics Co.Ltd. News
4594 FAQ
What was BrightPath Biotherapeutics Co.Ltd.’s price range in the past 12 months?
BrightPath Biotherapeutics Co.Ltd. lowest stock price was ¥43.00 and its highest was ¥114.00 in the past 12 months.
What is BrightPath Biotherapeutics Co.Ltd.’s market cap?
BrightPath Biotherapeutics Co.Ltd.’s market cap is ¥6.67B.
When is BrightPath Biotherapeutics Co.Ltd.’s upcoming earnings report date?
BrightPath Biotherapeutics Co.Ltd.’s upcoming earnings report date is Aug 07, 2026 which is in 35 days.
How were BrightPath Biotherapeutics Co.Ltd.’s earnings last quarter?
BrightPath Biotherapeutics Co.Ltd. released its earnings results on May 14, 2026. The company reported -¥2.63 earnings per share for the quarter, missing the consensus estimate of N/A by -¥2.63.
Is BrightPath Biotherapeutics Co.Ltd. overvalued?
According to Wall Street analysts BrightPath Biotherapeutics Co.Ltd.’s price is currently Overvalued.
Does BrightPath Biotherapeutics Co.Ltd. pay dividends?
BrightPath Biotherapeutics Co.Ltd. does not currently pay dividends.
What is BrightPath Biotherapeutics Co.Ltd.’s EPS estimate?
BrightPath Biotherapeutics Co.Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BrightPath Biotherapeutics Co.Ltd. have?
BrightPath Biotherapeutics Co.Ltd. has 138,891,300 shares outstanding.
What happened to BrightPath Biotherapeutics Co.Ltd.’s price movement after its last earnings report?
BrightPath Biotherapeutics Co.Ltd. reported an EPS of -¥2.63 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5.455%.
Which hedge fund is a major shareholder of BrightPath Biotherapeutics Co.Ltd.?
Currently, no hedge funds are holding shares in JP:4594
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BrightPath Biotherapeutics Co.Ltd.
BrightPath Biotherapeutics Co., Ltd. specializes in the development of innovative cancer immunotherapies. Among its leading candidates is GRN-1201, currently undergoing Phase II clinical studies for non-small cell lung cancer and Phase I studies for melanoma. The company's diverse development portfolio further encompasses BP1101, a neoantigen vaccine; BP1209, a platform for personalized neoantigen cancer vaccines; and BP1401, an agonist for toll-like receptor 9. Other therapeutic avenues include an induced pluripotent stem cell (iPSC)-derived regenerated NKT cell therapy aimed at head and neck cancer, and BP2301, an autologous HER2 chimeric antigen receptor-T (CAR-T) cell therapy targeting solid tumor sarcomas. Beyond its clinical-stage assets, BrightPath Biotherapeutics is also engaged in early-stage discovery efforts for new antibodies, including BP1200, which targets CD73; BP1210, an immune checkpoint inhibitor; and additional antibody candidates such as BP1202, BP1206, and BP1211. Established in Tokyo, Japan, in 2003, the company operated as GreenPeptide Co., Ltd. until its rebranding to BrightPath Biotherapeutics Co., Ltd. in July 2017.
Technical Analysis
Healios KK
―
StemRIM Inc.
―
CellSource Co., Ltd.
―
StemCell Institute
―
CellSeed Inc.
―